Cytological monitoring of peripheral blood, bronchoalveolar lavage fluid, and transbronchial biopsy specimens during acute rejection and cytomegalovirus infection in lung and heart–lung allograft recipients

Tikkanen, Jussi; Lemström, Karl; Halme, Maija; Pakkala, Seppo; Taskinen, Eero; Koskinen, Petri

doi:10.1034/j.1399-0012.2001.150201.x

Cited by 32 publications

(30 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-17 correlated with the severity of AR. In agreement with data from other authors, the present authors also found an increase in BAL lymphocytes [4,12] and neutrophils [8] in AR. This increase in BAL lymphocytes and neutrophils, in patients with an AR episode at day 28, did not normalise when analysed at a 2-month follow-up examination.…”

Section: Discussionsupporting

confidence: 83%

“…The current authors also found BAL neutrophils to be increased and to correlate with the grade of AR. This increase was also demonstrated in several other studies, although not consistently [8,17,18]. These papers clearly illustrate that neutrophils may be present in BAL during AR.…”

Section: Discussionsupporting

confidence: 61%

“…An important consideration is the cell profile variation by time as demonstrated by TIKKANEN et al [8]. The use of a fixed time-point for evaluation (,28 days after LTx) allows statistically adequate comparison between patients with rejection and patients without rejection.…”

Section: Discussionmentioning

confidence: 99%

“…In the pathophysiology of AR, after organ transplantation, lymphocytes are regarded as the main culprits, whereas the potential role of the neutrophils in AR is hardly mentioned [8,17,18]. Perhaps the idea that AR is characterised by a lymphocytic influx and chronic rejection by a neutrophilic influx should be revised.…”

Section: Il-17 Upregulation In Acute Lung Rejection Bm Vanaudenaerdmentioning

confidence: 99%

“…The current authors compared these results between patients with AR and patients with no rejection at an identical time point after LTx. As it has been shown that the cell profile in AR varies depending on the post-operative time [8], the first evaluation was performed at ,28 days after an LTx. A follow-up evaluation was performed 3 months after the LTx.…”

mentioning

confidence: 99%

See 4 more Smart Citations

The role of interleukin-17 during acute rejection after lung transplantation

Vanaudenaerde

Dupont²,

Wuyts³

et al. 2006

European Respiratory Journal

169

126

View full text Add to dashboard Cite

Acute rejection (AR) is an important complication that can occur after lung transplantation and constitutes a risk factor for bronchiolitis obliterans syndrome, which is characterised by a neutrophilic airway inflammation. The specific aim of this study was to investigate the role of interleukin (IL)-17, which promotes chemotaxis of neutrophils by inducing IL-8 production, in AR.Cell differentials, mRNA and protein levels were quantified in bronchoalveolar lavages (BALs) taken from patients at 28 and 90 days after lung transplantation. The patient's rejection status was assessed by transbronchial biopsy.An AR was found in nine out of the 26 patients examined, 28 days after transplantation. The number of BAL neutrophils and lymphocytes were increased in these patients. IL-17 mRNA and protein levels in the BAL were increased in patients with AR. Analysis of BAL obtained at day 90 after transplantation, demonstrated that the increase in IL-17 had disappeared, whereas the increase in neutrophils and lymphocytes persisted.These data showed that interleukin-17 is temporarily upregulated in bronchoalveolar lavage during acute rejection. The number of lymphocytes and neutrophils are increased in bronchoalveolar lavage during acute rejection and may persist up to 2 months after acute rejection. These findings suggest that interleukin-17 is important in the pathophysiology of acute lung rejection.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionsupporting

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Section: Il-17 Upregulation In Acute Lung Rejection Bm Vanaudenaerdmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

The role of interleukin-17 during acute rejection after lung transplantation

Vanaudenaerde

Dupont²,

Wuyts³

et al. 2006

European Respiratory Journal

169

126

View full text Add to dashboard Cite

show abstract

Histopathological Syndromes of Lung Allograft Rejection and Recurrent Disease

Farver

Wallace

2014

Textbook of Organ Transplantation

View full text Add to dashboard Cite

Immunosuppression and Allograft Rejection Following Lung Transplantation: Evidence to Date

Snell

Westall

Paraskeva

2013

Drugs

View full text Add to dashboard Cite

The enduring success of lung transplantation is built on the use of immunosuppressive drugs to stop the immune system from rejecting the newly transplanted lung allograft. Most patients receive a triple-drug maintenance immunosuppressive regimen consisting of a calcineurin inhibitor, an antiproliferative and corticosteroids. Induction therapy with either an antilymphocyte monoclonal or an interleukin-2 receptor antagonist are prescribed by many centres aiming to achieve rapid inhibition of recently activated and potentially alloreactive T lymphocytes. Despite this generic approach acute rejection episodes remain common, mandating further fine-tuning and augmentation of the immunosuppressive regimen. While there has been a trend away from cyclosporine and azathioprine towards a preference for tacrolimus and mycophenolate mofetil, this has not translated into significant protection from the development of chronic lung allograft dysfunction, the main barrier to the long-term success of lung transplantation. This article reviews the problem of lung allograft rejection and the evidence for immunosuppressive regimens used both in the short- and long-term in patients undergoing lung transplantation.

show abstract

Cytological monitoring of peripheral blood, bronchoalveolar lavage fluid, and transbronchial biopsy specimens during acute rejection and cytomegalovirus infection in lung and heart–lung allograft recipients

Cited by 32 publications

References 32 publications

The role of interleukin-17 during acute rejection after lung transplantation

The role of interleukin-17 during acute rejection after lung transplantation

Histopathological Syndromes of Lung Allograft Rejection and Recurrent Disease

Immunosuppression and Allograft Rejection Following Lung Transplantation: Evidence to Date

Contact Info

Product

Resources

About